Previous studies have shown that tumor mutation burden (TMB), fPD1, and tumor immunogenicity score can correlate with the objective response for ICB treatment in TCGA pan-cancer (Lee and Ruppin, 2019; Wang et al., 2019; Yarchoan et al., 2017). The gene discussed is PNKD; the disease is cancer.